175 related articles for article (PubMed ID: 31249879)
21. Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer.
Sun W; Du Y; Liang X; Yu C; Fang J; Lu W; Guo X; Tian J; Jin Y; Zheng J
Biomaterials; 2019 Oct; 217():119264. PubMed ID: 31260883
[TBL] [Abstract][Full Text] [Related]
22. The effects of β-caryophyllene oxide and trans-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice.
Hanušová V; Caltová K; Svobodová H; Ambrož M; Skarka A; Murínová N; Králová V; Tomšík P; Skálová L
Biomed Pharmacother; 2017 Nov; 95():828-836. PubMed ID: 28903178
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model.
Liu CM; Lee WC; Yu CY; Lan KL; Chang CH; Ting G; Lee TW
Oncol Rep; 2012 Mar; 27(3):678-84. PubMed ID: 22109644
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin-Stitched Polysaccharide Vesicles for Synergistic Cancer Therapy of Triple Antagonistic Drugs.
Deshpande NU; Jayakannan M
Biomacromolecules; 2017 Jan; 18(1):113-126. PubMed ID: 28064505
[TBL] [Abstract][Full Text] [Related]
26. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
27. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
28. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
29. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
[TBL] [Abstract][Full Text] [Related]
30. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer.
López-Camacho E; Trilla-Fuertes L; Gámez-Pozo A; Dapía I; López-Vacas R; Zapater-Moros A; Lumbreras-Herrera MI; Arias P; Zamora P; Vara JÁF; Espinosa E
Biomed Pharmacother; 2022 May; 149():112844. PubMed ID: 35339109
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
[TBL] [Abstract][Full Text] [Related]
33. Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo.
Lothstein L; Soberman J; Parke D; Gandhi J; Sweatman T; Seagroves T
Oncol Res; 2020 Dec; 28(5):451-465. PubMed ID: 32430093
[TBL] [Abstract][Full Text] [Related]
34. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
35. Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Alsherbiny MA; Bhuyan DJ; Low MN; Chang D; Li CG
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576262
[TBL] [Abstract][Full Text] [Related]
36. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer.
Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z
J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609
[TBL] [Abstract][Full Text] [Related]
37. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
38. Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway.
Lei S; Fan P; Wang M; Zhang C; Jiang Y; Huang S; Fang M; He Z; Wu A
Exp Ther Med; 2020 Aug; 20(2):1630-1636. PubMed ID: 32742395
[TBL] [Abstract][Full Text] [Related]
39. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates.
Cheng J; Khin KT; Davis ME
Mol Pharm; 2004; 1(3):183-93. PubMed ID: 15981921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]